Most human studies of CBD have been done on people who have seizures, and the FDA recently approved the first CBD-based drug, Epidiolex, for rare forms of epilepsy. Clinical trials for other conditions are promising, but tiny. In one Brazilian study published in 2011 of people with generalized social anxiety disorder, for example, taking a 600-mg dose of CBD (higher than a typical dose from a tincture) lessened discomfort more than a placebo, but only a dozen people were given the pill.
CannabiGold’s unique selling point is not its oil, however, but its method of application. A common customer issue is droppers leaking because, when the highly viscous oil gets in the rim of a conventional dropper, it is not easy to close the bottle tightly anymore. By listening to their customers and conducting research and testing in their state-of-the-art facilities, the R&D team at CannabiGold developed a precise dropper technology that would allow 10g of CBD oil to be delivered in 400 micro drops, one at a time.